Swiss National Bank Trims Stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Swiss National Bank trimmed its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 3.4% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 362,600 shares of the biopharmaceutical company’s stock after selling 12,800 shares during the quarter. Swiss National Bank owned 0.28% of Alnylam Pharmaceuticals worth $85,323,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in ALNY. Atria Investments Inc lifted its stake in Alnylam Pharmaceuticals by 78.9% in the third quarter. Atria Investments Inc now owns 3,145 shares of the biopharmaceutical company’s stock worth $865,000 after acquiring an additional 1,387 shares during the period. GSA Capital Partners LLP raised its holdings in shares of Alnylam Pharmaceuticals by 55.3% in the 3rd quarter. GSA Capital Partners LLP now owns 2,860 shares of the biopharmaceutical company’s stock valued at $787,000 after purchasing an additional 1,018 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. boosted its stake in shares of Alnylam Pharmaceuticals by 0.5% during the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 278,241 shares of the biopharmaceutical company’s stock valued at $76,525,000 after purchasing an additional 1,294 shares in the last quarter. Victory Capital Management Inc. boosted its stake in shares of Alnylam Pharmaceuticals by 10.9% during the third quarter. Victory Capital Management Inc. now owns 42,909 shares of the biopharmaceutical company’s stock valued at $11,801,000 after purchasing an additional 4,229 shares in the last quarter. Finally, Oppenheimer & Co. Inc. increased its holdings in Alnylam Pharmaceuticals by 11.1% during the third quarter. Oppenheimer & Co. Inc. now owns 1,906 shares of the biopharmaceutical company’s stock valued at $524,000 after buying an additional 190 shares during the period. Institutional investors own 92.97% of the company’s stock.

Insider Transactions at Alnylam Pharmaceuticals

In related news, CMO Pushkal Garg sold 1,548 shares of the firm’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $251.67, for a total value of $389,585.16. Following the transaction, the chief marketing officer now directly owns 11,989 shares of the company’s stock, valued at approximately $3,017,271.63. This trade represents a 11.44 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Jeffrey V. Poulton sold 967 shares of the firm’s stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $255.17, for a total value of $246,749.39. Following the completion of the transaction, the chief financial officer now owns 32,786 shares in the company, valued at approximately $8,366,003.62. This trade represents a 2.86 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 71,234 shares of company stock valued at $19,958,097 in the last ninety days. 1.50% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several analysts have issued reports on ALNY shares. William Blair reaffirmed an “outperform” rating on shares of Alnylam Pharmaceuticals in a research report on Wednesday, February 26th. Chardan Capital reiterated a “buy” rating and issued a $300.00 target price on shares of Alnylam Pharmaceuticals in a research note on Wednesday, February 26th. Royal Bank of Canada reissued an “outperform” rating and set a $310.00 price target on shares of Alnylam Pharmaceuticals in a research report on Wednesday, February 26th. Needham & Company LLC reaffirmed a “buy” rating and issued a $320.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Wednesday, February 26th. Finally, Morgan Stanley increased their target price on shares of Alnylam Pharmaceuticals from $275.00 to $284.00 and gave the company an “equal weight” rating in a research report on Friday, February 14th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and twenty have given a buy rating to the company’s stock. According to MarketBeat, Alnylam Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $304.26.

Alnylam Pharmaceuticals Price Performance

NASDAQ:ALNY opened at $241.76 on Friday. The firm has a market cap of $31.30 billion, a price-to-earnings ratio of -111.41 and a beta of 0.39. Alnylam Pharmaceuticals, Inc. has a one year low of $141.98 and a one year high of $304.39. The firm’s fifty day moving average is $255.02 and its two-hundred day moving average is $260.44. The company has a debt-to-equity ratio of 15.27, a quick ratio of 2.71 and a current ratio of 2.78.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.03). Research analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.